Comparative Pharmacology
Head-to-head clinical analysis: CENESTIN versus PMB 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENESTIN versus PMB 400.
CENESTIN vs PMB 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and exerting effects on reproductive tissues, bone, cardiovascular system, and CNS.
PMB 400 is a combination of progesterone and micronized estradiol; progesterone suppresses gonadotropin secretion and transforms proliferative endometrium into secretory endometrium, while estradiol replaces endogenous estrogen production and promotes growth of reproductive tissues.
0.45 mg orally once daily; titrate up to 1.25 mg once daily based on symptoms. Maximum dose 1.25 mg/day.
1 tablet (400 mg Pregabalin, 400 mg Mirogabalin, 100 mg Benfotiamine) orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-24 hours for conjugated estrogens; this long half-life allows for once-daily dosing and sustained estrogenic effects.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may be prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal, with approximately 90% excreted in urine as glucuronide and sulfate conjugates; about 10% excreted in feces via bile.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism via CYP3A4 produces inactive metabolites, with biliary/fecal excretion of metabolites (20-30%) and parent compound (<5%).
Category C
Category C
Estrogen
Estrogen/Progestin Combination